OVID — Ovid Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1636651 ·
Last close
$2.45
Market Cap
$457.27M
52W High
$3.11
52W Low
$1.55
ADV30
2,055,276
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -17,846,000 | -16,988,000 | 225,628,000 | 94,064,000 | 27,359,000 |
| Dec 2025 | 718,000 | — | -12,293,000 | 9,663,000 | 150,934,000 | 13,153,000 | 20,274,000 |
| Sep 2025 | 132,000 | — | -12,523,000 | -12,158,000 | 63,848,000 | 20,611,000 | 19,150,000 |
| Jun 2025 | 6,272,000 | — | -5,073,000 | -4,684,000 | 77,428,000 | 28,415,000 | 21,639,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,334,000
Investing CF
$-49,854,000
Financing CF
$75,207,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.31
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-321,713,000
Inventory
—
Receivables
—
ST Investments
$56,482,000
EBIT TTM
$-42,439,000
Pretax Income TTM
$-17,414,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,122,000
EBITDA
$-47,568,000
Free Cash Flow
$-20,216,376
Enterprise Value
$318,549,056
Total Cash
$155,522,000
Total Debt
$13,070,000
Shares Out
186,640,102
Trailing EPS
$-0.21
Book Value
$1.00
ROE
-18.8%
ROA
-19.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,252,000 | -42,439,000 | -17,414,000 | 150,934,000 | 20,274,000 | — | -38,334,000 |
| Dec 2024 | 566,000 | -61,885,000 | -26,433,000 | 92,167,000 | 23,941,000 | — | -55,956,000 |
| Dec 2023 | 392,000 | -59,281,000 | -52,339,000 | 144,027,000 | 56,229,000 | — | -45,781,000 |
| Dec 2022 | 1,502,748 | -55,547,651 | -54,169,029 | 155,265,814 | 22,993,250 | — | -55,227,127 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$173,000
NetIncome TTM
$-14,006,000
OpCashFlow TTM
$0
Assets (Latest)
$92,167,000
Forward EPS
$-0.45
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $2.45 · call oi: 1,356 · put oi: 641
Expected Move to 2026-10-16:
±$1.30
(53.06%) —
implied range
$1.15 –
$3.75
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CYDY | CytoDyn Inc. | $457.62M | $0.34 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $456.91M | $28.75 | — |
| KMDA | KAMADA LTD | $458.60M | $7.95 | — |
| FULC | Fulcrum Therapeutics, Inc. | $450.44M | $6.76 | — |
| FBRX | Forte Biosciences, Inc. | $449.31M | $21.94 | — |
News headlines (Yahoo Finance, 1h cache)
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
2026-05-14 10:51 · Yahoo
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
2026-05-12 11:00 · Yahoo
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks
2026-05-10 04:01 · Yahoo
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
2026-04-08 12:00 · Yahoo
Ovid Therapeutics Q4 Earnings Call Highlights
2026-03-18 21:47 · Yahoo
Here's Why Ovid Therapeutics Stock Popped Higher Today
2026-03-18 18:37 · Yahoo
Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC Meeting
2026-03-18 13:28 · Yahoo
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
2026-03-18 11:50 · Yahoo
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-18 10:05 · Yahoo
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
2026-03-18 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.